drugset
Drugs / Adalimumab biosimilar
last change Aug 2023 re-read 3 minutes ago

Adalimumab biosimilar

also known as Hyrimoz
Developed for
spondyloarthropathy
Investigated by
Novartis Pharmaceuticals

Trials 1

today NCT03906136 · Ph 3
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT03906136 Jun 2019 → Feb 2022 spondyloarthropathy Novartis Pharmaceuticals Completed Missed primary

Press releases naming this drug 9 releases

DateIssuerRelease
2023-08-23 Sandoz Sandoz AG expands reach of Hyrimoz® (adalimumab-adaz) in US through commercialization agreement with Cordavis sandoz.com ↗
2023-07-01 Novartis Pharmaceuticals Sandoz to launch Hyrimoz® (adalimumab-adaz) high-concentration formulation, marking Sandoz entrance into US immunology space novartis.com ↗
2023-04-03 Novartis Pharmaceuticals Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation novartis.com ↗
2023-03-21 Novartis Pharmaceuticals Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation novartis.com ↗
2023-01-30 Sandoz Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar sandoz.com ↗
2023-01-30 Novartis Pharmaceuticals Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar novartis.com ↗
2022-07-21 Novartis Pharmaceuticals Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF) novartis.com ↗
2018-10-31 Novartis Pharmaceuticals Sandoz receives US FDA approval for biosimilar Hyrimoz(TM) (adalimumab-adaz) novartis.com ↗
2018-07-27 Novartis Pharmaceuticals Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab) novartis.com ↗

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Adalimumab biosimilar “switched to adalimumab biosimilar (Hyrimoz®) 40 mg s.c. every 2 weeks until Week 34.” NCT03906136 ↗
Known as Hyrimoz “switched to adalimumab biosimilar (Hyrimoz®) 40 mg s.c. every 2 weeks until Week 34.” NCT03906136 ↗
Route Subcutaneous “switched to adalimumab biosimilar (Hyrimoz®) 40 mg s.c. every 2 weeks until Week 34.” NCT03906136 ↗